NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.40+0.17 (+2.73%)
Close on Nov 13, 2026Market cap $29.30MP/E –Yield 0.00%
NextCure ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
NextCure's ebitda for the twelve months ending Dec 31, 2021 was -$66.47M. For fiscal 2025 it was -$55.42M. The highest annual figure on record is -$21.52M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$55.42M | – |
| FY2024 | Dec 31, 2024 | -$56.85M | – |
| FY2023 | Dec 31, 2023 | -$63.94M | – |
| FY2022 | Dec 31, 2022 | -$71.81M | – |
| FY2021 | Dec 31, 2021 | -$66.47M | – |
| FY2020 | Dec 31, 2020 | -$37.83M | – |
| FY2019 | Dec 31, 2019 | -$34.79M | – |
| FY2018 | Dec 31, 2018 | -$21.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | -$17.86M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.13M | -280.0% |
| Q4 FY2020 | Dec 31, 2020 | -$15.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.51M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.01M | – |
| Q1 FY2020 | Mar 31, 2020 | $8.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.26M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.91M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.25M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.42M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.63M | – |
See a number that looks wrong?